论文部分内容阅读
本研究目的旨在确定大剂量熊去氧胆酸(ＵｒｓｏｄｅｏｘｙｃｈｏｌｉｃＡｃｉｄ,ＵＤＣＡ)治疗原发性硬化性胆管炎 (ＰＳＣ)的耐受性和安全性。方法 研究对象为 1 998年 1月至 7月曼彻斯特Ｍａｙｏ诊所 3 0例ＰＳＣ病人。ＰＳＣ诊断标准为 :慢性胆汁淤积性肝病至少 6个月 ;血
The purpose of this study was to determine the tolerability and safety of high-dose Ursodeoxycholic Acid (UDCA) in the treatment of primary sclerosing cholangitis (PSC). Methods Subjects were 30 PSC patients at the Mayo Clinic in Manchester, January-July 1998. PSC diagnostic criteria: chronic cholestatic liver disease at least 6 months; blood